Table 2. Characteristics of other malignancies.
| Characteristics | N=108 |
|---|---|
| Type of OM, n (%) | |
| Hematological | 17 (16) |
| Non-hematological | 17 (16) |
| OM incidence above the median age, n (%) | 16 (33) |
| OM incidence according to FCR treatment, n (%) | |
| ≤4 cycles | 16 (35) |
| 6 cycles | 18 (29) |
| Hematological OM, n (%) | |
| Richter’s syndrome | 7 (7) |
| Myelodysplastic syndrome | 6 (6) |
| Acute myeloid leukemia | 3 (3) |
| Acute lymphoid leukemia | 1 (1) |
| Non-hematological OM, n (%) | |
| Non-melanoma skin cancers | 7 (7) |
| Prostate cancer | 4 (4) |
| Lung cancer | 3 (3) |
| Breast cancer | 2 (2) |
| Colon cancer | 1 (1) |
| Median time to OM onset from diagnosis, months (range) | 99.2 (3-329) |
| Median time to OM onset after FCR treatment, months (range) | 61.8 (2-181) |
| Richter’s syndrome | 84.1 (2-112) |
| Therapy-related myeloid neoplasia | 82.8 (28-181) |
| Non-hematological | 59.2 (9-159) |
OM=other malignancy; FCR=fludarabine, cyclophosphamide and rituximab; n=number.